Frequently asked questions about BioAFM

Do you have a question about BioAFM? This article will tell you everything you need to know.

Biogen CEO seeks ‘awful lot more collaborations’ to beef up R&D as it launches postpartum depression, Alzheimer’s and ALS drugs

Biogen CEO Chris Viehbacher said the famed Boston biotech is ready to do “an awful lot more collaborations” as it seeks to fill out its

November 9, 2023

Looking for Source of Knee Implant Failure? Biomarkers May Help

SAN FRANCISCO — Tests for certain metals could help clinicians determine why knee replacements appear to be failing, according to preliminary studies reported here. For

February 17, 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;as monotherapy in patients

December 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.